Early discontinuation of endocrine therapy for breast cancer: Who is at risk in clinical practice?

SpringerPlus

Volumn 3, Issue 1, 2014, Pages 1-10

  Kemp, Anna ^a   Preen, David B ^a   Saunders, Christobel ^a   Boyle, Frances ^b   Bulsara, Max ^c   Malacova, Eva ^a   Roughead, Elizabeth E ^d  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF NOTRE DAME   (Australia)

^d UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

45 and up study; Adherence; Aromatase inhibitors; Persistence; Tamoxifen

Indexed keywords

EID: 84904014760     PISSN: None     EISSN: 21931801     Source Type: Journal    
DOI: 10.1186/2193-1801-3-282     Document Type: Article

References (49)

1. 45 and Up Study Collaborators: Cohort profile: the 45 and Up Study. Int J Epidemiol 2008, 37(5): 941-947.
2. ATAC Trialists' Group: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005, 365: 60-62.
3. Australian Bureau of Statistics: 3412. 0 - Migration, Australia, 2011-12 and 2013-13. 2013. http://www. abs. gov. au/ausstats/abs@. nsf/Lookup/3412. 0Chapter12011-12%20and%202012-13. Accessed April 8 2014.
4. Australian Government Department of Health: Schedule of pharmaceutical benefits, 1 October 2013. Department of Health. 2013. http://www. pbs. gov. au/pbs/home. Accessed October 31 2013.
5. Australian Government Department of Health: Fees, patient contributions and safety net thresholds, history of PBS copayments and safety net thresholds. Department of Health. 2013. http://www. pbs. gov. au/info/healthpro/explanatory-notes/front/fee. Accessed October 31 2013.
6. Australian Population and Migration Research Centre: Accessibility and Remoteness Index of Australia (ARIA). The University of Adelaide. 2013. http://adelaide. edu. au/apmrc/research/projects/category/about_aria. html. Accessed October 31 2013.
7. Barron TI, Connolly RM, Bennett K, Feely J, Kennedy MJ: Early discontinuation of tamoxifen: a lesson for oncologists. Cancer 2007, 109(5): 832-839.
8. Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, Sahmoud T, ATAC (Arimidex TAoiCTG): Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003, 98: 1802-1810.
9. Bell JB, Fradkin P, Schwarz M, Davis SR: Understanding discontinuation of oral adjuvant endocrine therapy by women with hormone receptor-positive invasive breast cancer nearly 4 years from diagnosis. Menopause 2013, 20(1): 1-5.
10. Bliss JM, Kilburn LS, Coleman RE, Forbes JF, Coates AS, Jones SE, Jassem J, Delozier T, Andersen J, Paridaens R, van de Velde CJH, Lonning PE, Morden J, Reise J, Cisar L, Menschik T, Coombes RC: Disease-related outcomes with long-term follow-up: an updated analysis of the Intergroup Exemestane Study. J Clin Oncol 2012, 30(7): 709-717. doi: 10. 1200/jco. 2010. 33. 7899.
11. Centre for Health Record Linkage (CHeReL): Information for researchers. CHeReL. 2009. http://www. cherel. org. au/. Accessed October 31 2013.
12. Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40(5): 373-383.
13. Cheung KL: Endocrine therapy for breast cancer: an overview. Breast 2007, 16: 327-343.
14. Chim K, Xie SX, Stricker CT, Li QS, Gross R, Farrar JT, DeMichele A, Mao JJ: Joint pain severity predicts premature discontinuation of aromatase inhibitors in breast cancer survivors. BMC Cancer 2013, 13: 401.
15. Coates A, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Láng I, Del Mastro L, Smith I, Chirgwin J, Nogaret J, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A: Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007, 25: 486-492.
16. Davies C, Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013, 381(9869): 805-816.
17. Demissie S, Silliman RA, Lash TL: Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J Clin Oncol 2001, 19(2): 322-328.
18. Earle CC, Nattinger AB, Potosky AL, Lang K, Mallick R, Berger M, Warren JL: Identifying cancer relapse using SEER-Medicare data. Med Care 2002, 40(8): IV-75-IV-81.
19. Fallowfield L, Cella D, Cuzick J, Francis S, Locker G, Howell A: Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) adjuvant breast cancer trial. J Clin Oncol 2004, 22(21): 4261-4271. doi: 10. 1200/jco. 2004. 08. 029.
20. Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M: Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008, 9(1): 45-53.
21. Gray RG, aTTom Collaborative Group: aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6, 953 women with early breast cancer. J Clin Oncol 2013., 31(suppl, abstract 5):.
22. Grunfeld EA, Hunter MS, Sikka P, Mittal S: Adherence beliefs among breast cancer patients taking tamoxifen. Patient Educ Couns 2005, 59(1): 97-102. http://www. sciencedirect. com/science/article/pii/S0738399104003350.
23. Güth U, Myrick ME, Schötzau A, Kilic N, Schmid SM: Drug switch because of treatment-related adverse side effects in endocrine adjuvant breast cancer therapy: how often and how often does it work?Breast Cancer Res Treat 2011, 129(3): 799-807. http://dx. doi. org/10. 1007/s10549-011-1668-y.
24. Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai W-Y, Fehrenbacher L, Gomez SL, Miles S, Neugut AI: Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8, 769 early-stage breast cancer patients. J Clin Oncol 2010. doi: 10. 1200/jco. 2009. 25. 9655.
25. Hsieh K-P, Chen L-C, Cheung K-L, Chang C-S, Yang Y-H: Interruption and non-adherence to long-term adjuvant hormone therapy is associated with adverse survival outcome of breast cancer women - an Asian population-based study. PLoS One 2014, 9(2): e87027. doi: 10. 1371/journal. pone. 0087027.
26. Huiart L, Dell'Aniello S, Suissa S: Use of tamoxifen and aromatase inhibitors in a large population-based cohort of women with breast cancer. Br J Cancer 2011, 104(10): 1558-1563. doi: 10. 1038/bjc. 2011. 140.
27. Jordan VC, Obiorah I, Fan P, Kim HR, Ariazi E, Cunliffe H, Brauch H: Evolution of long-term adjuvant anti-hormone therapy: consequences and opportunities. The St. Gallen prize lecture. Breast 2011, 20(Suppl 3): S1-S11.
28. Kemp A, Roughead E, Preen DB, Glover J, Semmens J: Determinants of self-reported medicine underuse due to cost: a comparison of seven countries. J Health Serv Res Pol 2010, 15(2): 106-114.
29. Kemp A, Preen D, Glover J, Semmens J, Roughead E: How much do we spend on prescription medicines? Out-of-pocket costs for patients in Australia and other OECD countries. Aust Health Rev 2011, 35: 341-349.
30. Kimmick G, Anderson R, Camacho F, Bhosle M, Hwang W, Balkrishnan R: Adjuvant hormonal therapy use among insured, low-income women with breast cancer. J Clin Oncol 2009, 27(21): 3445-3451. doi: 10. 1200/jco. 2008. 19. 2419.
31. Lamont EB, Herndon JE, Weeks JC, Henderson IC, Earle CC, Schilsky RL: Measuring disease-free survival and cancer relapse using Medicare claims from CALGB Breast Cancer Trial Participants (companion to 9344). J Natl Cancer Inst 2006, 98(18): 1335-1338.
32. McCowan C, Shearer J, Donnan PT, Dewar JA, Crilly M, Thompson AM, Fahey TP: Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer 2008, 99: 1763-1768.
33. Murphy C, Bartholomew L, Carpentier M, Bluethmann S, Vernon S: Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat 2012, 134(2): 459-478. doi: 10. 1007/s10549-012-2114-5.
34. NBCC: Clinical practice guidelines for the management of early breast cancer: second edition. NBCC, NHMRC. 2001. http://www. nhmrc. gov. au/guidelines/publications/cp74. Accessed October 31 2013.
35. Nekhlyudov L, Li L, Ross-Degnan D, Wagner AK: Five-year patterns of adjuvant hormonal therapy use, persistence, and adherence among insured women with early-stage breast cancer. Breast Cancer Res Treat 2011, 130(2): 681-689.
36. Neugut AI, Subar M, Wilde ET, Stratton S, Brouse CH, Hillyer GC, Grann VR, Hershman DL: Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. J Clin Oncol 2011, 29(18): 2534-2542. doi: 10. 1200/jco. 2010. 33. 3179.
37. Organisation for Economic Co-operation and Development: 2011 PPP benchmark results. OECD. 2014. http://stats. oecd. org/. Accessed April 15 2014.
38. Owusu C, Buist D, Field T, Lash T, Thwin S, Geiger A: Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol 2008, 26(4): 549-555.
39. Partridge AH, Wang PS, Winer EP, Avorn J: Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 2003, 21(4): 602-606.
40. Partridge A, LaFountain A, Mayer E, Taylor B, Winer E, Asnis-Alibozek A: Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 2008, 26(4): 556-562.
41. Sedjo R, Devine S: Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer. Breast Cancer Res Treat 2011, 125(1): 191-200. doi: 10. 1007/s10549-010-0952-6.
42. Sehdev S, Martin G, Sideris L, Lam W, Brisson S: Safety of adjuvant endocrine therapies in hormone receptor-positive early breast cancer. Curr Oncol 2009, 16(Suppl 2): S14-S23.
43. Stokes M, Thompson D, Montoya EL, Weinstein MC, Winer EP, Earle CC: Ten-year survival and cost following breast cancer recurrence: estimates from SEER-Medicare data. Value Health 2008, 11(2): 213-220.
44. Swedish Breast Cancer Cooperative Group: Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst 1996, 88(21): 1543-1549. doi: 10. 1093/jnci/88. 21. 1543.
45. van Herk-Sukel MP, van de Poll-Franse LV, Voogd AC, Nieuwenhuijzen GAP, Coebergh JWW, Herings RMC: Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis. Breast Cancer Res Treat 2010, 122(3): 843-851.
46. Viale G, Regan MM, Dell'Orto P, Mastropasqua MG, Maiorano E, Rasmussen BB, MacGrogan G, Forbes JF, Paridaens RJ, Colleoni M, Láng I, Thürlimann B, Mouridsen H, Mauriac L, Gelber RD, Price KN, Goldhirsch A, Gusterson BA, Coates AS, Collaborative ftB-: Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. Ann Oncol 2011. doi: 10. 1093/annonc/mdq738.
47. Weaver K, Camacho F, Hwang W, Anderson R, Kimmick G: Adherence to adjuvant hormonal therapy and its relationship to breast cancer recurrence and survival among low-income women. Am J Clin Oncol 2013, 36: 181-187.
48. Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, Cobleigh MA, Mamounas EP, Goldstein LJ, Whelan TJ, Powles TJ, Bryant J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Somerfield MR: American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005, 23(3): 619-629. doi: 10. 1200/jco. 2005. 09. 121.
49. Yood MU, Owusu C, Buist DSM, Geiger AM, Field TS, Thwin SS, Lash TL, Prout MN, Wei F, Quinn VP, Frost FJ, Silliman RA: Mortality impact of less-than-standard therapy in older breast cancer patients. J Am Coll Surg 2008, 206(1): 66-75. http://dx. doi. org/10. 1016/j. jamcollsurg. 2007. 07. 015.